Won't Elan shareholders nix Theravance deal?
This article was originally published in Scrip
There's been a lot of buzz around yesterday's announcement by Elan that it is to pay $1 billion for a 21% share of Theravance's royalties from some – but not all – of the respiratory products it has partnered with GlaxoSmithKline (scripintelligence.com, 13 May 2013). To summarize the buzz, it has mostly been along the lines of "What a great deal for Theravance!" (the company's share price went up 17.9%; its executives indicated this had been a rapidly arranged agreement and refused to discuss whether they'd shopped their offer around) and "What is Elan doing?" (the company's ADRs went down 1.44%).
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.